Oryzon to join the IBEX Small Cap Index
The inclusion will become effective on December 24th
MADRID, Spain and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today that the Technical Advisory Committee of the IBEX INDICES has decided to incorporate Oryzon to the Ibex Small Cap Index together with other five small-cap companies. This change will take effect as of December 24. The index adjustment will be made at the closing of the session on Friday 21.
The IBEX SMALL CAP index is composed of 30 stocks of the Spanish Stock Exchange that follow certain requirements in terms of stock market capitalization, free floating capital and annual rotation of the value. The IBEX SMALL CAP is a national and international benchmark for the stock market evolution of Spanish medium and small capitalization companies.
Carlos Buesa, CEO of Oryzon, commented that "being part of this index is indeed very positive news for a company like Oryzon, as it will allow us to continue improving the visibility in front of a wider range of investors. Likewise, it will allow us to be considered for certain investment instruments like index funds and others, and it also highlights the high degree of liquidity of our stock in the Spanish market."
Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. Oryzon has one of the strongest portfolios in the field. Oryzon’s LSD1 program has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon has offices in Spain and the United States. For more information, visit www.oryzon.com
This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates” and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forward?looking statements, whether as a result of new information, future events or otherwise. This press release is not an offer of securities for sale in the United States or any other jurisdiction. Oryzon’s securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of Oryzon’s securities to be made in the United States will be made by means of a prospectus that may be obtained from Oryzon or the selling security holder, as applicable, that will contain detailed information about Oryzon and management, as well as financial statements.
|The Trout Group||ATREVIA||Emili Torrell|
|Thomas Hoffmann||Patricia Cobo||BD Director|
|+1 646 378 2932||+34 91 564 07 25||+34 93 515 13 13|
Upcoming Life Sciences Events
- September 2019
- Munich: The Biotech & Pharma Summit: Drug Delivery & Formulation
- Brussels: The Pharma Forecasting Course
- Bangkok: Bio Investment Asia 2019